The event brought together 36 industry representatives (from across 19 innovative companies) and 40+ University of Oxford academics and clinicians (from across 19 university departments) to discuss the challenges being faced by industry in addressing AMR.
AIMdays offer a low barrier route for small companies to meet with our academic and clinical community. Small and medium-sized companies represented on the day included Astrego Diagnostics, GeneFirst, Ingenza and Summit Therapeutics. We were also delighted to welcome a good number of larger pharmaceutical companies (including Evotec, GSK & Thermo Fisher Scientific) and organisations such as AHSN North East & North Cumbria, Innovate UK and Release Life Sciences & Diagnostics.
"The AIMday enabled me to meet academics with research interests close to my own, but from departments I wouldn't usually interact with" - Alastair Parkes, Evotec.
The day was packed with opportunities for cross-disciplinary discussions and networking. There were 25 workshops and topics discussed including:
- Implementation and adoption of point of care tests
- Quantifying the effect of the immune system on the emergence of resistance
- Stewardship associated with the use of new antibiotics
- Access through the bacterial cell envelope for the development of new antibiotics
- Use of machine learning to enhance the efficacy of new antimicrobials
- Funding gaps in AMR research
“Excellent event! We received tangible, practical advice on some of the technical challenges we are facing for our early stage antibacterial programmes” – Ajay Mistry, Oppilotech